Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF432 (ImmuneEditome ID:9668)

1. Gene summary of enriched editing regions for ZNF432

Gene summary

Gene information	Gene symbol	ZNF432
	Gene ID	9668
	GeneSynonyms	-
	GeneCytomap	19q13.41
	GeneType	protein-coding
	GeneDescription	zinc finger protein 432
	GeneModificationdate	20230518
	UniprotID	O94892;M0QZ71;M0R0H8;M0R0E2;M0R258
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:52031705-52032758:-	ENST00000594154.4	ENSG00000256087.5	ZNF432	UTR3	AluSp,L1MD3,L1MD2,AluSq2	chr19:52031705-52032758:-.alignment
chr19:52051158-52051382:-	ENST00000598446.1	ENSG00000256087.5	ZNF432	ncRNA_intronic	AluSx	chr19:52051158-52051382:-.alignment
chr19:52057835-52057981:-	ENST00000598446.1	ENSG00000256087.5	ZNF432	ncRNA_intronic	AluSx	chr19:52057835-52057981:-.alignment

Top

2. Tumor-specific enriched editing regions for ZNF432

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr19:52031705-52032758:-	BRCA	EER	5.7747e-07
ENSG00000256087.5,ZNF432	BRCA	EAG	2.0009e-06
chr19:52031705-52032758:-	COAD	EER	2.0373e-02
chr19:52031705-52032758:-	KIRC	EER	7.3393e-06
ENSG00000256087.5,ZNF432	KIRC	EAG	7.8522e-03
chr19:52031705-52032758:-	LUAD	EER	1.2576e-05
ENSG00000256087.5,ZNF432	LUAD	EAG	1.1405e-02
chr19:52031705-52032758:-	LUSC	EER	1.2657e-02
chr19:52031705-52032758:-	PRAD	EER	2.8422e-02
chr19:52031705-52032758:-	THCA	EER	3.7537e-07
ENSG00000256087.5,ZNF432	THCA	EAG	1.5726e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000256087.5,ZNF432	BLCA	Path	EAG	8.8118e-03	2.7714e-03	0.1504
chr19:52031705-52032758:-	BLCA	Path	EER	6.8494e-03	2.2136e-03	0.1539
chr19:52031705-52032758:-	KICH	Path	EER	8.2870e-03	3.1147e-03	0.3612
ENSG00000256087.5,ZNF432	KICH	Path	EAG	1.6584e-02	1.7722e-03	0.3804
chr19:52031705-52032758:-	THCA	Path	EER	2.0038e-04	2.4735e-04	0.1627
ENSG00000256087.5,ZNF432	THCA	Path	EAG	8.5288e-04	1.0412e-03	0.1458

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr19:52031705-52032758:-	LUAD	EER	1.3369e-02	1.5777e-02	7.7465e+00

Top

3. Enriched editing regions and immune related genes for ZNF432

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:52031705-52032758:-

KICH

EER

ENSG00000196199,MPHOSPH8

0.5784

3.9176e-02

3.3854e-06

0.5403

DGCR8;FBL

Macrophages_M2

GSVA_HALLMARK_UV_RESPONSE_DN

chr19:52031705-52032758:-

THCA

EER

ENSG00000110200,ANAPC15

-0.5171

2.0481e-31

4.1678e-32

-0.4922

DGCR8;FBL

T_cells_CD8

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr19:52031705-52032758:-

THCA

EER

ENSG00000269044,CTC-429P9.3

-0.5066

1.2846e-30

1.2665e-27

-0.4590

DGCR8;FBL

NK_cells_activated

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr19:52031705-52032758:-

THCA

EER

ENSG00000170364,SETMAR

-0.4823

1.0433e-27

2.2846e-27

-0.4569

DGCR8;FBL

NK_cells_activated

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

chr19:52031705-52032758:-

THCA

EER

ENSG00000203778,FAM229B

-0.4909

1.1962e-27

3.7850e-26

-0.4472

FBL

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr19:52031705-52032758:-

THCA

EER

ENSG00000278133,RP11-196G11.5

-0.4820

5.6947e-27

5.0047e-26

-0.4462

DGCR8;FBL

NK_cells_resting

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

chr19:52031705-52032758:-

THCA

EER

ENSG00000174915,PTDSS2

-0.4833

9.9506e-27

1.2524e-22

-0.4171

DGCR8;FBL

NK_cells_activated

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr19:52031705-52032758:-

THCA

EER

ENSG00000163832,ELP6

-0.4782

4.0584e-26

7.1816e-28

-0.4609

DGCR8;FBL

NK_cells_activated

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr19:52031705-52032758:-

THCA

EER

ENSG00000157765,SLC34A2

0.4711

8.3895e-26

2.9481e-29

0.4715

DGCR8;FBL

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr19:52031705-52032758:-

THCA

EER

ENSG00000197165,SULT1A2

-0.4650

6.3696e-25

4.8025e-21

-0.4024

Dendritic_cells_resting

GSVA_HALLMARK_APOPTOSIS

More results

Top

4. Enriched editing regions and immune related splicing for ZNF432

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:52031705-52032758:-

BLCA

EER

ENSG00000076604.10

chr17

28747015:28747119:28747212:28747264

-0.2428

6.8713e-06

2.8977e-14

-0.4115

DGCR8;FBL

TRAF4

T_cells_CD4_memory_activated

GSVA_HALLMARK_UV_RESPONSE_UP

chr19:52031705-52032758:-

ESCA

EER

ENSG00000184349.8

chr5

107381237:107381376:107387234:107387315:107387705:107387771

-0.3758

1.1167e-03

4.9126e-07

-0.4257

DGCR8;FBL

Plasma_cells

GSVA_HALLMARK_KRAS_SIGNALING_DN

chr19:52031705-52032758:-

ESCA

EER

ENSG00000254413.4

chr22

50568868:50571292:50571374:50571533

0.3284

2.9487e-02

1.6182e-08

0.4384

DGCR8;FBL

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_BILE_ACID_METABOLISM

chr19:52031705-52032758:-

ESCA

EER

ENSG00000066117.10

chr12

50086755:50086878:50087362:50087485:50088520:50088637

-0.3439

2.2070e-02

2.3228e-08

-0.4314

DGCR8;FBL

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

chr19:52031705-52032758:-

PAAD

EER

ENSG00000182646.12

chrX

52956272:52956346:52957087:52957123

-0.3038

3.8903e-02

2.3279e-08

-0.4314

Macrophages_M2

GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

chr19:52031705-52032758:-

PAAD

EER

ENSG00000132780.12

chr1

45609299:45610995:45613168:45613248

-0.2741

4.0767e-02

1.3099e-07

-0.4493

DGCR8;FBL

T_cells_CD4_memory_activated

GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

ENSG00000256087.5,ZNF432

PAAD

EAG

ENSG00000182646.12

chrX

52956272:52956346:52957087:52957123

-0.2963

4.3510e-02

4.8742e-09

-0.4497

Macrophages_M2

GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

chr19:52031705-52032758:-

PAAD

EER

ENSG00000144895.7

chr3

150563514:150564381:150567692:150567766

-0.3910

2.1759e-03

2.7163e-08

-0.4093

DGCR8;FBL

NK_cells_activated

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr19:52031705-52032758:-

PAAD

EER

ENSG00000074582.8

chr2

218659771:218660421:218660938:218661217

-0.3406

2.5659e-03

1.7250e-07

-0.4407

DGCR8;FBL

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000256087.5,ZNF432

PAAD

EAG

ENSG00000128159.7

chr22

50219956:50220015:50220250:50220416

-0.3714

4.5991e-03

1.1451e-08

-0.4204

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1

T_cells_CD4_memory_activated

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

5. Enriched editing regions and immune infiltration for ZNF432

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr19:52031705-52032758:-	ACC	EER	B_cells_memory	1.2373e-02	0.2802
ENSG00000256087.5,ZNF432	ACC	EAG	B_cells_memory	1.0787e-02	0.2854
chr19:52031705-52032758:-	BLCA	EER	Macrophages_M1	4.8023e-07	0.2510
ENSG00000256087.5,ZNF432	BLCA	EAG	Macrophages_M1	4.2828e-07	0.2517
chr19:52031705-52032758:-	BRCA	EER	Macrophages_M1	5.4456e-04	0.1060
ENSG00000256087.5,ZNF432	BRCA	EAG	Macrophages_M1	1.2228e-04	0.1172
chr19:52031705-52032758:-	CESC	EER	T_cells_CD4_memory_activated	7.0059e-04	0.1989
ENSG00000256087.5,ZNF432	CESC	EAG	T_cells_CD4_memory_activated	4.9258e-03	0.1644
chr19:52031705-52032758:-	CHOL	EER	NK_cells_resting	6.4444e-03	-0.4646
ENSG00000256087.5,ZNF432	CHOL	EAG	T_cells_follicular_helper	1.6121e-02	0.4157
chr19:52031705-52032758:-	COAD	EER	B_cells_naive	2.1781e-02	-0.1468
ENSG00000256087.5,ZNF432	COAD	EAG	B_cells_naive	3.9658e-02	-0.1305
chr19:52031705-52032758:-	DLBC	EER	Mast_cells_resting	1.2808e-03	0.4652
ENSG00000256087.5,ZNF432	DLBC	EAG	Mast_cells_resting	8.6379e-05	0.5514
chr19:52031705-52032758:-	ESCA	EER	T_cells_regulatory_(Tregs)	4.9026e-03	-0.2256
ENSG00000256087.5,ZNF432	ESCA	EAG	Macrophages_M1	3.0431e-02	0.1723
chr19:52031705-52032758:-	GBM	EER	Macrophages_M0	1.8624e-02	-0.1830
ENSG00000256087.5,ZNF432	GBM	EAG	Macrophages_M0	1.4275e-02	-0.1904
chr19:52031705-52032758:-	HNSC	EER	T_cells_regulatory_(Tregs)	4.2874e-03	-0.1442
ENSG00000256087.5,ZNF432	HNSC	EAG	T_cells_regulatory_(Tregs)	1.6635e-02	-0.1192
chr19:52031705-52032758:-	KICH	EER	Eosinophils	4.9095e-03	0.3448
ENSG00000256087.5,ZNF432	KICH	EAG	Eosinophils	6.3156e-04	0.4128
chr19:52031705-52032758:-	KIRC	EER	Mast_cells_resting	1.2526e-03	-0.1665
ENSG00000256087.5,ZNF432	KIRC	EAG	Mast_cells_resting	2.0814e-02	-0.1187
chr19:52031705-52032758:-	KIRP	EER	T_cells_CD4_memory_resting	7.5564e-03	-0.1616
ENSG00000256087.5,ZNF432	KIRP	EAG	T_cells_regulatory_(Tregs)	1.1114e-02	-0.1532
chr19:52031705-52032758:-	LAML	EER	Macrophages_M1	1.6981e-02	0.4729
ENSG00000256087.5,ZNF432	LAML	EAG	Eosinophils	1.0237e-04	0.4631
chr19:52031705-52032758:-	LGG	EER	Neutrophils	7.5722e-03	0.1173
ENSG00000256087.5,ZNF432	LGG	EAG	Neutrophils	1.4694e-02	0.1070
chr19:52031705-52032758:-	LIHC	EER	Macrophages_M0	4.1881e-02	-0.1329
chr19:52031705-52032758:-	LUAD	EER	Dendritic_cells_activated	2.1904e-02	0.1089
ENSG00000256087.5,ZNF432	LUAD	EAG	Eosinophils	2.3762e-02	-0.1054
chr19:52031705-52032758:-	LUSC	EER	T_cells_CD4_memory_activated	2.5955e-02	0.1066
ENSG00000256087.5,ZNF432	LUSC	EAG	T_cells_CD4_memory_activated	1.6400e-02	0.1140
chr19:52031705-52032758:-	MESO	EER	Mast_cells_resting	8.3354e-04	-0.3663
ENSG00000256087.5,ZNF432	MESO	EAG	Mast_cells_resting	1.4535e-03	-0.3501
chr19:52031705-52032758:-	OV	EER	T_cells_CD8	1.0897e-03	0.1902
ENSG00000256087.5,ZNF432	OV	EAG	T_cells_CD8	1.4963e-05	0.2504
chr19:52031705-52032758:-	PAAD	EER	NK_cells_resting	7.3630e-03	0.2037
ENSG00000256087.5,ZNF432	PAAD	EAG	NK_cells_resting	1.1637e-02	0.1898
chr19:52031705-52032758:-	PCPG	EER	T_cells_CD4_memory_resting	4.3286e-03	-0.2117
ENSG00000256087.5,ZNF432	PCPG	EAG	T_cells_CD4_memory_resting	1.5392e-03	-0.2344
chr19:52031705-52032758:-	PRAD	EER	T_cells_CD4_memory_resting	8.9628e-04	0.1485
ENSG00000256087.5,ZNF432	PRAD	EAG	T_cells_CD4_memory_resting	3.8453e-06	0.2053
chr19:52031705-52032758:-	SARC	EER	T_cells_CD8	1.6940e-03	0.2008
ENSG00000256087.5,ZNF432	SARC	EAG	Macrophages_M1	1.8342e-02	0.1494
chr19:52031705-52032758:-	SKCM	EER	T_cells_CD8	3.4758e-03	0.1460
ENSG00000256087.5,ZNF432	SKCM	EAG	T_cells_CD8	9.7302e-04	0.1621
chr19:52031705-52032758:-	STAD	EER	T_cells_CD4_memory_activated	5.3088e-03	0.1531
ENSG00000256087.5,ZNF432	STAD	EAG	Dendritic_cells_activated	3.7748e-04	0.1917
chr19:52031705-52032758:-	TGCT	EER	Macrophages_M2	3.8091e-04	-0.2819
ENSG00000256087.5,ZNF432	TGCT	EAG	Dendritic_cells_resting	1.1130e-02	-0.2034
chr19:52031705-52032758:-	THCA	EER	NK_cells_activated	2.3532e-05	-0.1872
ENSG00000256087.5,ZNF432	THCA	EAG	NK_cells_activated	1.1292e-05	-0.1942
chr19:52031705-52032758:-	THYM	EER	Macrophages_M1	1.7026e-04	0.3408
ENSG00000256087.5,ZNF432	THYM	EAG	T_cells_gamma_delta	4.9540e-05	0.3645
chr19:52031705-52032758:-	UCEC	EER	Macrophages_M1	1.0257e-02	0.1953
ENSG00000256087.5,ZNF432	UCEC	EAG	Dendritic_cells_activated	1.7206e-02	0.1804
chr19:52031705-52032758:-	UCS	EER	T_cells_CD4_memory_activated	7.7072e-03	0.3525
ENSG00000256087.5,ZNF432	UCS	EAG	T_cells_CD4_memory_resting	2.0082e-02	-0.3100
ENSG00000256087.5,ZNF432	UVM	EAG	T_cells_regulatory_(Tregs)	2.8874e-02	0.3260

Top

6. Enriched editing regions and immune gene sets for ZNF432

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr19:52031705-52032758:-	BLCA	EER	4.4573e-04	0.1765	8.9888e-04	0.1671	3.1985e-04	0.1808	9.7226e-09	0.2846
ENSG00000256087.5,ZNF432	BLCA	EAG	1.1144e-03	0.1638	4.6666e-04	0.1757	6.9626e-04	0.1704	1.2090e-10	0.3173
chr19:52031705-52032758:-	LUAD	EER	2.6970e-03	0.1422	6.7053e-03	0.1286	3.7340e-03	0.1375	1.7711e-04	0.1772
ENSG00000256087.5,ZNF432	LUAD	EAG	6.0347e-04	0.1593	3.1396e-02	0.1004	1.7068e-03	0.1459	5.7892e-07	0.2305
ENSG00000256087.5,ZNF432	PRAD	EAG	2.2673e-02	0.1021	2.2553e-04	0.1646	1.0799e-03	0.1461	1.1192e-02	0.1136
ENSG00000256087.5,ZNF432	STAD	EAG	7.7989e-04	0.1814	3.9438e-02	0.1118	3.8059e-02	0.1126	3.5544e-03	0.1577

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr19:52031705-52032758:-	ACC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	5.4242e-03	0.3100
ENSG00000256087.5,ZNF432	ACC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	4.2021e-03	0.3187
chr19:52031705-52032758:-	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	7.6211e-14	0.3656
ENSG00000256087.5,ZNF432	BLCA	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	2.6483e-13	0.3577
ENSG00000256087.5,ZNF432	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.2038e-17	0.2542
chr19:52031705-52032758:-	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.4490e-22	0.2938
ENSG00000256087.5,ZNF432	CESC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.6321e-05	0.2497
chr19:52031705-52032758:-	CESC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.2549e-06	0.2815
ENSG00000256087.5,ZNF432	CHOL	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.2584e-02	0.4296
chr19:52031705-52032758:-	COAD	GSVA_HALLMARK_COMPLEMENT	EER	2.4157e-04	0.2330
ENSG00000256087.5,ZNF432	COAD	GSVA_HALLMARK_COMPLEMENT	EAG	5.4938e-05	0.2527
ENSG00000256087.5,ZNF432	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	1.7135e-05	0.3348
chr19:52031705-52032758:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	2.0184e-04	0.2952
chr19:52031705-52032758:-	GBM	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.6046e-05	-0.3289
ENSG00000256087.5,ZNF432	GBM	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	6.9744e-05	-0.3046
ENSG00000256087.5,ZNF432	HNSC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	6.0538e-06	0.2232
chr19:52031705-52032758:-	HNSC	GSVA_HALLMARK_COMPLEMENT	EER	2.7362e-03	0.1511
ENSG00000256087.5,ZNF432	KICH	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.0697e-03	0.3517
chr19:52031705-52032758:-	KICH	GSVA_HALLMARK_MYC_TARGETS_V1	EER	4.9937e-03	0.3442
ENSG00000256087.5,ZNF432	KIRC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.4058e-08	0.2862
chr19:52031705-52032758:-	KIRC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.1042e-06	0.2491
chr19:52031705-52032758:-	KIRP	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	1.4377e-04	0.2285
ENSG00000256087.5,ZNF432	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	5.8163e-05	0.2404
ENSG00000256087.5,ZNF432	LAML	GSVA_HALLMARK_APICAL_SURFACE	EAG	1.7489e-02	-0.2939
chr19:52031705-52032758:-	LGG	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.4890e-08	0.2396
ENSG00000256087.5,ZNF432	LGG	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	4.3666e-09	0.2540
ENSG00000256087.5,ZNF432	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	5.8564e-10	0.3790
chr19:52031705-52032758:-	LIHC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	3.7786e-08	0.3493
ENSG00000256087.5,ZNF432	LUAD	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	1.1110e-08	0.2624
chr19:52031705-52032758:-	LUAD	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	1.9936e-05	0.2012
ENSG00000256087.5,ZNF432	LUSC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	3.3016e-04	0.1698
chr19:52031705-52032758:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.3002e-06	0.2144
chr19:52031705-52032758:-	MESO	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	7.1302e-04	0.3707
ENSG00000256087.5,ZNF432	MESO	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	7.4594e-03	0.2970
chr19:52031705-52032758:-	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	8.5042e-13	0.4025
ENSG00000256087.5,ZNF432	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.1709e-08	0.3260
ENSG00000256087.5,ZNF432	PAAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.6374e-04	0.2612
chr19:52031705-52032758:-	PAAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.5440e-04	0.2693
ENSG00000256087.5,ZNF432	PCPG	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	6.6577e-03	0.2016
chr19:52031705-52032758:-	PCPG	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	3.2861e-03	0.2180
chr19:52031705-52032758:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.6213e-04	0.1684
ENSG00000256087.5,ZNF432	PRAD	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	9.1673e-06	0.1973
ENSG00000256087.5,ZNF432	READ	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.9823e-05	0.4426
chr19:52031705-52032758:-	READ	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0490e-04	0.4152
ENSG00000256087.5,ZNF432	SARC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	4.0410e-05	0.2571
chr19:52031705-52032758:-	SARC	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	4.7258e-05	0.2584
ENSG00000256087.5,ZNF432	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.8338e-05	0.2096
chr19:52031705-52032758:-	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.5474e-06	0.2272
chr19:52031705-52032758:-	STAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.7617e-10	0.3419
ENSG00000256087.5,ZNF432	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.0951e-08	0.2981
ENSG00000256087.5,ZNF432	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EAG	7.5218e-05	-0.3125
chr19:52031705-52032758:-	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EER	1.5298e-06	-0.3750
chr19:52031705-52032758:-	THCA	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	1.9982e-18	0.3766
ENSG00000256087.5,ZNF432	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.2532e-20	0.3985
ENSG00000256087.5,ZNF432	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.6984e-08	0.4846
chr19:52031705-52032758:-	THYM	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	3.4888e-07	0.4504
chr19:52031705-52032758:-	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.5317e-07	0.3734
ENSG00000256087.5,ZNF432	UCEC	GSVA_HALLMARK_HEME_METABOLISM	EAG	2.0289e-05	0.3170
ENSG00000256087.5,ZNF432	UCS	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	1.7934e-02	0.3153
chr19:52031705-52032758:-	UCS	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.0571e-02	0.3391

Top

7. Enriched editing regions and drugs for ZNF432

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr19:52031705-52032758:-	ACC	AZD.0530	EER	1.9077e-04	0.4079
ENSG00000256087.5,ZNF432	ACC	AZD.0530	EAG	7.0929e-04	0.3730
chr19:52031705-52032758:-	BLCA	AICAR	EER	6.2195e-12	-0.3380
ENSG00000256087.5,ZNF432	BLCA	AICAR	EAG	1.4783e-12	-0.3469
ENSG00000256087.5,ZNF432	BRCA	JNK.Inhibitor.VIII	EAG	1.0330e-04	-0.1185
chr19:52031705-52032758:-	BRCA	JNK.Inhibitor.VIII	EER	2.3931e-07	-0.1579
chr19:52031705-52032758:-	CESC	FH535	EER	2.5531e-03	0.1774
ENSG00000256087.5,ZNF432	CESC	BMS.708163	EAG	2.0346e-04	-0.2161
chr19:52031705-52032758:-	CHOL	Methotrexate	EER	3.0966e-02	-0.3820
ENSG00000256087.5,ZNF432	CHOL	KU.55933	EAG	2.8352e-02	-0.3818
chr19:52031705-52032758:-	COAD	BI.D1870	EER	3.4672e-03	-0.1864
ENSG00000256087.5,ZNF432	COAD	BI.D1870	EAG	4.7340e-04	-0.2199
ENSG00000256087.5,ZNF432	DLBC	FTI.277	EAG	4.8269e-02	-0.2961
ENSG00000256087.5,ZNF432	ESCA	AICAR	EAG	4.3615e-05	-0.3192
chr19:52031705-52032758:-	ESCA	AICAR	EER	2.9813e-07	-0.3989
ENSG00000256087.5,ZNF432	GBM	A.443654	EAG	2.3523e-04	0.2826
chr19:52031705-52032758:-	GBM	BIBW2992	EER	7.1206e-05	-0.3042
chr19:52031705-52032758:-	HNSC	Elesclomol	EER	2.7126e-05	0.2105
ENSG00000256087.5,ZNF432	HNSC	DMOG	EAG	1.0061e-04	-0.1925
ENSG00000256087.5,ZNF432	KICH	LFM.A13	EAG	1.1596e-02	0.3113
chr19:52031705-52032758:-	KICH	BAY.61.3606	EER	1.0201e-02	-0.3165
ENSG00000256087.5,ZNF432	KIRC	CI.1040	EAG	4.5342e-05	-0.2079
chr19:52031705-52032758:-	KIRC	CI.1040	EER	1.1599e-04	-0.1983
ENSG00000256087.5,ZNF432	KIRP	EHT.1864	EAG	6.3274e-05	0.2392
chr19:52031705-52032758:-	KIRP	EHT.1864	EER	1.2956e-04	0.2300
ENSG00000256087.5,ZNF432	LAML	LFM.A13	EAG	1.3124e-02	0.3062
chr19:52031705-52032758:-	LGG	GSK269962A	EER	1.3581e-15	0.3419
ENSG00000256087.5,ZNF432	LGG	GSK269962A	EAG	1.6278e-16	0.3516
ENSG00000256087.5,ZNF432	LIHC	AICAR	EAG	2.6037e-06	-0.2922
chr19:52031705-52032758:-	LIHC	GSK.650394	EER	5.1654e-05	0.2609
chr19:52031705-52032758:-	LUAD	AUY922	EER	2.0576e-03	-0.1461
ENSG00000256087.5,ZNF432	LUAD	BMS.509744	EAG	6.9367e-06	-0.2079
ENSG00000256087.5,ZNF432	LUSC	JW.7.52.1	EAG	6.3632e-03	-0.1294
chr19:52031705-52032758:-	LUSC	JW.7.52.1	EER	1.8743e-03	-0.1485
ENSG00000256087.5,ZNF432	MESO	BMS.708163	EAG	2.8507e-03	-0.3294
chr19:52031705-52032758:-	MESO	BMS.708163	EER	1.0333e-02	-0.2852
chr19:52031705-52032758:-	OV	KU.55933	EER	6.2303e-07	-0.2872
ENSG00000256087.5,ZNF432	OV	KU.55933	EAG	4.6973e-05	-0.2362
chr19:52031705-52032758:-	PAAD	AUY922	EER	1.6626e-03	-0.2381
ENSG00000256087.5,ZNF432	PAAD	CEP.701	EAG	9.5843e-03	0.1982
ENSG00000256087.5,ZNF432	PCPG	BI.2536	EAG	1.7960e-02	0.1762
chr19:52031705-52032758:-	PCPG	BI.2536	EER	3.1544e-02	0.1603
ENSG00000256087.5,ZNF432	PRAD	CEP.701	EAG	1.7075e-07	0.2317
chr19:52031705-52032758:-	PRAD	CEP.701	EER	5.0435e-05	0.1808
ENSG00000256087.5,ZNF432	READ	BMS.708163	EAG	3.1964e-04	-0.3790
chr19:52031705-52032758:-	READ	BMS.754807	EER	1.2004e-02	-0.2762
ENSG00000256087.5,ZNF432	SARC	AZD6482	EAG	2.6560e-03	-0.1897
chr19:52031705-52032758:-	SARC	Cisplatin	EER	1.8836e-05	-0.2712
ENSG00000256087.5,ZNF432	SKCM	LFM.A13	EAG	8.4388e-05	-0.1927
chr19:52031705-52032758:-	SKCM	GW843682X	EER	2.1373e-05	0.2110
chr19:52031705-52032758:-	STAD	KU.55933	EER	1.0657e-06	-0.2648
ENSG00000256087.5,ZNF432	STAD	KU.55933	EAG	5.4298e-04	-0.1866
chr19:52031705-52032758:-	TGCT	MG.132	EER	5.3330e-05	0.3186
ENSG00000256087.5,ZNF432	TGCT	MG.132	EAG	4.6578e-06	0.3584
ENSG00000256087.5,ZNF432	THCA	AICAR	EAG	7.1678e-20	-0.3911
chr19:52031705-52032758:-	THCA	AICAR	EER	4.7116e-16	-0.3509
ENSG00000256087.5,ZNF432	THYM	CEP.701	EAG	9.1515e-10	0.5265
chr19:52031705-52032758:-	THYM	BI.D1870	EER	4.1971e-06	0.4109
ENSG00000256087.5,ZNF432	UCEC	BMS.536924	EAG	1.4787e-08	0.4130
chr19:52031705-52032758:-	UCEC	ABT.888	EER	4.8947e-04	-0.2631
ENSG00000256087.5,ZNF432	UCS	AZD.2281	EAG	3.9456e-03	-0.3792
chr19:52031705-52032758:-	UCS	Cisplatin	EER	6.9547e-04	-0.4398
ENSG00000256087.5,ZNF432	UVM	CHIR.99021	EAG	4.7975e-02	-0.2965
chr19:52031705-52032758:-	UVM	CHIR.99021	EER	2.2056e-02	-0.3444

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType